An open-label Phase I trial to evaluate the pharmacokinetics and safety profile of BAY 94-9027 following single and multiple dose administration in two cohorts of previously treated male subjects with severe hemophilia A
|Effective start/end date||6/1/10 → 5/31/13|
- BAYER HEALTHCARE PHARMACEUTICALS
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.